SEC Form 4 filed by Chief Medical Officer Ozden Rabia Gurses

$ADVM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $ADVM alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ozden Rabia Gurses

(Last) (First) (Middle)
C/O ADVERUM BIOTECHNOLOGIES, INC.
100 CARDINAL WAY

(Street)
REDWOOD CITY CA 94063

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Adverum Biotechnologies, Inc. [ ADVM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/02/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $7.15 08/02/2024 A 44,010 (1) 08/01/2034 Common Stock 44,010 $0 44,010 D
Explanation of Responses:
1. 1/3 of the total number of shares subject to the Option shall vest and become exercisable on the first anniversary of August 2, 2024 (the "Vesting Commencement Date"), and 1/36 of the total number of shares subject to the Option shall vest and become exercisable each month thereafter, such that all of the shares shall become vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.
/s/ John Rakow, Attorney-in-Fact 08/06/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $ADVM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ADVM

DatePrice TargetRatingAnalyst
6/25/2024$25.00Outperform
Oppenheimer
4/30/2024$30.00Buy
H.C. Wainwright
7/7/2022$4.00Hold → Buy
Truist
7/23/2021Hold → Neutral
Cantor Fitzgerald
7/23/2021$23.00 → $3.00Overweight → Neutral
Cantor Fitzgerald
7/23/2021$5.00 → $2.00Market Perform
SVB Leerink
More analyst ratings

$ADVM
Press Releases

Fastest customizable press release news feed in the world

See more
  • Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

    Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMDARTEMIS is the first-ever initiation of a registrational intravitreal gene therapy trial in patients with wet AMDNon-inferiority study to evaluate a single Ixo-vec injection compared to on-label aflibercept 2mg in both treatment-naïve and previously treated patients REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today announ

    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 44,380 shares of common stock and restricted stock units (RSUs) for 22,790 shares of common stock to 5 new employees under Adverum's 2017 Inducement Plan. The Compensation Committee of Adverum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $4.20 per share, Adverum's closing

    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

    REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the Cowen 45th Annual Healthcare Life Sciences Conference on Tuesday, March 4 at 11:50 a.m. ET. The webcast of the presentation may be accessed under Events and Presentations in the Investors section of Adverum's website. A replay of the webcast will be available on the website for at least 30 days following the event. About Adverum Biotechnologies Adverum Biotechnologies (NASDAQ:ADVM) is a clinical-stage company that

    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ADVM
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ADVM
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ADVM
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ADVM
SEC Filings

See more

$ADVM
Leadership Updates

Live Leadership Updates

See more
  • Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

    - 52-week LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024 - Appointed Jason Mitchell as chief commercial officer - On track to initiate pivotal program in 1H 2025 - $153.2 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter of 2024 and provided updates to anticipated milestones. "We remain laser focused on initiating

    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

    REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of Jason L. Mitchell as chief commercial officer. Mr Mitchell brings to Adverum over 20 years of commercial experience, including in retinal disease, and most recently oversaw the successful launch of SYFOVRE® in geographic atrophy (GA). In his new role, Mr. Mitchell will be responsible for setting the launch strategy and building the commercial infrastructure for ixoberogene soroparvovec (Ixo-vec), Adverum's potential one-time intravitreal (IVT) injec

    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights

    - 6E10 dose of Ixo-vec selected for Phase 3 pivotal trials - LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class product profile of Ixo-vec, with similar efficacy and a favorable safety profile compared to OPTIC - LUNA 9-month landmark analysis and pivotal trial design update anticipated in 4Q 2024 - $173.8 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reporte

    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ADVM
Financials

Live finance-specific insights

See more
  • Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting

    REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the interim 26-week landmark data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) being presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The webcast will be held on Wednesday, July 17 at 8:00 a.m. ET and will include a presentation from Dr. Charles C. Wykoff, Director of Res

    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

    - Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annual Meeting of the Macula Society, with company-sponsored webcast on Thursday, February 8, 2024 at 8:00am ET - REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review preliminary efficacy and safety data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related

    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

    REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024. "We are very pleased to have the opportunity to present our initial Phase 2 efficacy and safety data from the LUNA study at the Macula Society meeting" stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies. "We recently received confirmation that ou

    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ADVM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more